

**ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**  
**(Incorporation in Malaysia)**

**REPORTS AND FINANCIAL**  
**STATEMENTS: 31 MARCH 2020**

**ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**  
**(Incorporated in Malaysia)**

|           | <b>TABLE OF CONTENTS</b>                                    | <b>PAGE</b> |
|-----------|---|-------------|
| <b>1.</b> | <b>DIRECTORS' REPORT</b>                                    | <b>2</b>    |
| <b>2.</b> | <b>STATEMENT BY DIRECTORS AND<br/>STATUTORY DECLARATION</b> | <b>6</b>    |
| <b>3.</b> | <b>INDEPENDENT AUDITORS' REPORT<br/>TO THE MEMBERS</b>      | <b>7</b>    |
| <b>4.</b> | <b>STATEMENT OF FINANCIAL POSITION</b>                      | <b>12</b>   |
| <b>5.</b> | <b>STATEMENT OF PROFIT OR LOSS</b>                          | <b>13</b>   |
| <b>6.</b> | <b>STATEMENT OF CHANGES IN EQUITY</b>                       | <b>14</b>   |
| <b>7.</b> | <b>STATEMENT OF CASH FLOWS</b>                              | <b>15</b>   |
| <b>8.</b> | <b>NOTES TO THE FINANCIAL STATEMENTS</b>                    | <b>16</b>   |

**ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**  
**(Incorporated in Malaysia)**

**DIRECTORS' REPORT**  
**FOR THE FINANCIAL YEAR ENDED 31 MARCH 2020**

The Directors have pleasure in presenting their annual report and the audited financial statements of the Company for the financial year ended 31 March 2020.

**PRINCIPAL ACTIVITIES**

The principal activities of the Company are intended to be the business of general trading. There has been no significant change in the nature of the Company's activities to the date of this report.

**RESULTS**

|   | <b>2020</b><br><b>RM</b> |
|---|--------------------------|
| <b>LOSS FOR THE FINANCIAL<br/>YEAR AFTER TAXATION</b> | <u><u>(17,489)</u></u>   |

**DIVIDENDS**

No dividends have been paid or declared since the end of the previous financial year. The Directors do not recommend that a dividend be paid in respect of the current financial year.

**RESERVES AND PROVISIONS**

All material transfers to or from reserves or provisions during the financial year have been properly disclosed in the financial statements.

**SHARES AND DEBENTURES**

The Company did not issue any new shares or debentures during the financial year.



## SHARE OPTIONS

No options have been granted by the Company to any parties during the financial year to subscribe for unissued shares of the Company.

No shares have been issued during the financial year by virtue of the exercise of any options to subscribe for unissued shares of the Company. At the end of the financial year, there were no unissued shares of the Company under options.

## VALUATION OF ASSETS AND LIABILITIES

Reasonable steps were taken to ascertain whether any current assets, were unlikely to realize in the ordinary course of business, their values as shown in the accounting records of the Company and a write down of the values of these current assets is not considered necessary.

At the date of this report, no circumstances have arisen which would render the values attributed to the current assets or the adherence to the existing method of valuation of the assets or the liabilities of the Company misleading or inappropriate.

## CONTINGENT AND OTHER LIABILITIES

At the date of this report, the assets of the Company have not been charged to secure the liabilities of any third parties and no contingent liabilities were undertaken during the financial year or have arisen since the end of the financial year.

No contingent or other liabilities have become enforceable or are likely to become enforceable within the succeeding period of twelve months which will or may substantially affect the ability of the Company to meet its obligations as and when they fall due.

## ITEMS OF AN UNUSUAL NATURE

At the date of this report, no circumstances have arisen which would render any amount stated in the financial statements misleading or substantially affect the results of the Company for the succeeding financial year.

In the opinion of the Directors: -

- a) the results of the Company during the financial year were not substantially affected by any item, transaction or event of a material and unusual nature; and
- b) there has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event of a material and unusual nature likely to affect substantially the results of the Company for the current financial year in which this report is made.



## DIRECTORS

Since the end of the previous financial year, no Director has received or become entitled to receive any benefit by reason of a contract made by the Company or a related corporation with the Director or with a firm of which the Director is a member or with a company in which the Director has a substantial financial interest.

There were no arrangements during and at the end of the financial year which had the object of enabling the Directors of the Company to acquire any benefit by means of the acquisition of shares in or debentures of the Company or any other body corporate.

The Directors in office at the date of this report in the Company during the financial year were as follows:

Mohana Kumar Pillai (*resigned w.e.f. 17.06.2020*)  
Lee Cheng Gaik

## DIRECTORS' REMUNERATION

None of the directors or past directors of the Company have received any remuneration from the Company during the financial year.

None of the directors or past directors of the Company have received any other benefit other than in cash from the Company during the financial year.

No payment are required to be paid to or payable to any third party in respect of the services provided to the Company by the directors or past directors of the Company during the financial year.

## INDEMNIFYING DIRECTORS, OFFICERS AND AUDITORS

Indemnities and insurance premium have been paid by the ultimate holding entity for the directors and officers of the Company during the financial year.

## HOLDING COMPANY

The Holding Company is **Strides Pharma Global Pte. Ltd.**, a company incorporated in Singapore.

**AUDITORS' REMUNERATION**

Total amount receivable by the auditors as remuneration for their services as auditors are as follows:

|                 | 2020<br>RM   |
|-----------------|--------------|
| Statutory Audit | <u>1,500</u> |

**AUDITORS**

The auditors, **MUSTAPHARAJ PLT** have given consent to accept nominations for reappointment as auditors of the Company for the ensuing financial year in accordance with Section 267(3) of the Companies Act, 2016.

Signed in accordance with a resolution  
of the Director on behalf of the Board



---

**LEE CHENG GAIK**

Dated : **1 8 SEP 2020**



**ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**  
(Incorporated in Malaysia)

**STATEMENT BY DIRECTOR**  
**PURSUANT TO SECTION 251(2) OF THE COMPANIES ACT, 2016**

We, **LEE CHENG GAIK**, being the sole Director of **ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**, hereby state that in our opinion, the financial statements set out on pages 13 to 23 are properly drawn up so as to give a true and fair view of the state of affairs of the Company at 31 March 2020 and of the results, changes in equity and of the cash flows for the financial year ended on that date in accordance with the provisions of the Companies Act, 2016 and Malaysian Private Entities Reporting Standard issued by the Malaysian Accounting Standards Board.

Signed in accordance with a resolution of the Board of Directors dated **18 SEP 2020**

**LEE CHENG GAIK**

**STATUTORY DECLARATION**  
**PURSUANT TO SECTION 251(1)(b) OF THE COMPANIES ACT, 2016**


I, **LEE CHENG GAIK**, being the Director primarily responsible for managing the affairs of **ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**, do solemnly and sincerely declare that the Statement of Financial Position and Statement of Profit or loss together with the Notes, Statement of Changes in Equity and Statement of Cash Flows, set out on pages 13 to 23, are to the best of my knowledge and belief correct and I make this solemn declaration conscientiously believing the same to be true and by virtue of the provisions of the Statutory Declarations Act, 1960.

Subscribe and solemnly declared by the  
above named at **Petaling Jaya** in the state

of **Selangor Darul Ehsan**

Dated : **18 SEP 2020**

BEFORE ME:



NO. 5, JALAN 14/30, SECTION 14,  
46100 PETALING JAYA,  
SELANGOR.

**ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**  
**(Incorporated in Malaysia)**  
**(Registration No. 201701016331 (1230495-V))**

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF  
ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**

*Report on the Financial Statements*

*Opinion*

We have audited the financial statements of **ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**, which comprise the statement of financial position as at 31 March 2020 and the statement of profit or loss, statement of changes in equity and the statement of cash flows for the financial year then ended and notes at the financial statements, including a summary of significant accounting policies as set out on pages 13 to 23.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the Company as of 31 March 2020 and of its financial performance and its cash flows for the financial year then ended in accordance with Malaysian Private Entities Reporting Standard and the requirements of the Companies Act, 2016 in Malaysia.

*Basis for Opinion*

We conducted our audit in accordance with approved standards on auditing in Malaysia and International Standards on Auditing. Our responsibilities under those standards are further described in the *Auditors' Responsibilities for the Audit of the Financial Statements* section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



**ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**  
**(Incorporated in Malaysia)**  
**(Registration No. 201701016331 (1230495-V))**

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF  
ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD. (CONT'D)**

***Independence and Other Ethical Responsibilities***

We are independent of the Company in accordance with the *By-Laws (on Professional Ethics, Conduct and Practice)* of the Malaysian Institute of Accountants ("By-Laws") and the International Ethics Standards Board for Accountants' *Code of Ethics for Professional Accountants* ("IESBA Code"), and we have fulfilled our other ethical responsibilities in accordance with the By-laws and the IESBA Code.

***Information Other than the Financial Statements and Auditors' Report Thereon***

The Directors of the Company are responsible for the other information. The other information comprises the Directors' Report but does not include the financial statements of the Company and our auditors' report thereon.

Our opinion on the financial statements of the Company does not cover the Directors' Report and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements of the Company, our responsibility is to read the Directors' Report and, in doing so, consider whether the Directors' Report is materially inconsistent with the financial statements of the Company or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If based on the work we have performed, we conclude that there is a material misstatement of the Directors' Report, we are required to report the fact. We have nothing to report in this regards.



**ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**  
**(Incorporated in Malaysia)**  
**(Registration No. 201701016331 (1230495-V))**

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF  
ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD. (CONT'D)**

***Responsibilities of the Directors for the Financial Statements***

The Directors of the Company are responsible for the preparation of financial statements of the Company that give a true and fair view in accordance with Malaysian Private Entities Reporting Standard and the requirements of the Companies Act, 2016 in Malaysia. The Directors are also responsible for such internal control as the Directors determine is necessary to enable the preparation for financial statements of the Company that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements of the Company, the Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

***Auditors' Responsibilities for the Audit of the Financial Statements***

Our objectives are to obtain reasonable assurance about whether the financial statements of the Company as a whole are free from material misstatement, whether due to fraud or error and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with approved standards on auditing in Malaysia and International Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.



**ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**  
**(Incorporated in Malaysia)**  
**(Registration No. 201701016331 (1230495-V))**

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF  
ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD. (CONT'D)**

*Auditors' Responsibilities for the Audit of the Financial Statements (cont'd)*

As part of an audit in accordance with approved standards on auditing in Malaysia and International Standards on Auditing, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements of the Company whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud or higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding in internal control relevant to the audit in order to design audit procedures that are appropriate to the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Directors.
- Conclude on the appropriateness of the Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements of the Company or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.



**ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**  
(Incorporated in Malaysia)  
(Registration No. 201701016331 (1230495-V))

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF  
ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD. (CONT'D)**

***Auditors' Responsibilities for the Audit of the Financial Statements (cont'd)***

- Evaluate the overall presentation, structure and contents of the financial statements of the Company, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

***Emphasis of Matter***

Without qualifying our opinion, we draw attention to page 13 where the Company has a deficit in its shareholders' funds of RM25,471 (2019 : RM7,982) as at the end of the financial year.

However, the financial statements have been properly drawn up on the basis of accounting principles applicable to a going concern. This basis presumes that the Company will continue to receive financial support from its related company and / or the business operations will be profitable in the foreseeable future and consequently the realisation of assets and the settlement of liabilities will occur in the ordinary course of business. Should these assumptions be negated, the preparation of the financial statements on a going concern basis may no longer be appropriate.

***Report on Other Legal and Regulatory Requirements***

In accordance with the requirements of the Companies Act, 2016 in Malaysia, we also report that in our opinion, the accounting and other records and the registers required by the Act to be kept by the Company have been properly kept in accordance with the provisions of the Act.





**MUSTAPHARAJ PLT**  
(201806000705(LLP0015086-LCA) & AF 001361)  
Chartered Accountants  
E-33-05 Dataran 32, No. 2, Jalan 19/1  
46300 Petaling Jaya, Selangor D. E.  
Tel: +603 7841 5500  
Fax: +603 7841 5501  
Email: audit@mustapharaj.com

**ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**  
(Incorporated in Malaysia)  
(Registration No. 201701016331 (1230495-V))

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF  
ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD. (CONT'D)**

*Other Matters*

This report is made solely to the members of the Company, as a body, in accordance with Section 266 of the Companies Act, 2016 in Malaysia and for no other purpose. We do not assume responsibility to any other person for the contents of this report.

---

**MUSTAPHARAJ PLT**  
(Firm No : AF 1361)  
Chartered Accountants  
(Malaysia)

---

**RALPH RAVIN RATNASWAMY**  
Approval No:  
Bil.3214/10/21 (J)

Dated : **18 SEP 2020**

**ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**  
**(Incorporated in Malaysia)**

**STATEMENT OF FINANCIAL POSITION AT 31 MARCH 2020**

|                                     | Note | 2020<br>RM      | 2019<br>RM     |
|-------------------------------------|------|-----------------|----------------|
| <b>CURRENT ASSETS</b>               |      |                 |                |
| Cash and Cash Equivalents           | 5    | <u>49,171</u>   | <u>64,131</u>  |
| <b>EQUITY</b>                       |      |                 |                |
| Share Capital                       |      | 5,000           | 5,000          |
| Share Application Monies            | 6    | 50,000          | 50,000         |
| Accumulated Losses                  |      | (80,471)        | (62,982)       |
| <b>SHAREHOLDER'S EQUITY</b>         |      | <u>(25,471)</u> | <u>(7,982)</u> |
| <b>CURRENT LIABILITIES</b>          |      |                 |                |
| Payables and Accruals               | 7    | 6,982           | 5,382          |
| Amount Due to Holding Company       | 8    | <u>67,660</u>   | <u>66,731</u>  |
|                                     |      | <u>74,642</u>   | <u>72,113</u>  |
| <b>TOTAL EQUITY AND LIABILITIES</b> |      | <u>49,171</u>   | <u>64,131</u>  |

The notes set out on pages 17 to 23, form an integral part of and should be read in conjunction with these financial statements.



**ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**  
**(Incorporated in Malaysia)**

**STATEMENT OF PROFIT OR LOSS**  
**FOR THE FINANCIAL YEAR ENDED 31 MARCH 2020**

|  | Note | 2020<br>RM             | 2019<br>RM             |
|--|------|------------------------|------------------------|
| <b>GROSS OPERATING REVENUE</b>                         |      | -                      | -                      |
| <b>OTHER INCOME</b>                                    | 9    | 16                     | 19                     |
| <b>ADMINISTRATIVE EXPENSES</b>                         |      | <u>(17,505)</u>        | <u>(33,354)</u>        |
| <b>LOSS FOR THE FINANCIAL YEAR<br/>BEFORE TAXATION</b> |      | (17,489)               | (33,335)               |
| <b>TAXATION</b>  | 10   | <u>-</u>               | <u>-</u>               |
| <b>LOSS FOR THE FINANCIAL YEAR<br/>AFTER TAXATION</b>  |      | <u><u>(17,489)</u></u> | <u><u>(33,335)</u></u> |

The notes set out on pages 17 to 23, form an integral part of and should be read in conjunction with these financial statements.

**ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**  
**(Incorporated in Malaysia)**

**STATEMENT OF CHANGES IN EQUITY**  
**FOR THE FINANCIAL YEAR ENDED 31 MARCH 2020**

|   | SHARE<br>CAPITAL<br>RM | SHARE<br>APPLICATION<br>MONIES<br>RM | ACCUMULATED<br>LOSSES<br>RM | TOTAL<br>RM     |
|---|------------------------|--------------------------------------|-----------------------------|-----------------|
| <b>2020</b>                                   |                        |                                      |                             |                 |
| At 1 April 2019                               | 5,000                  | 50,000                               | (62,982)                    | (7,982)         |
| Loss for the Financial Year<br>after Taxation | -                      | -                                    | (17,489)                    | (17,489)        |
| At 31 March 2020                              | <u>5,000</u>           | <u>50,000</u>                        | <u>(80,471)</u>             | <u>(25,471)</u> |
| <b>2019</b>                                   |                        |                                      |                             |                 |
| At 1 April 2018                               | 5,000                  | 50,000                               | (29,647)                    | 25,353          |
| Loss for the Financial Year<br>after Taxation | -                      | -                                    | (33,335)                    | (33,335)        |
| At 31 March 2019                              | <u>5,000</u>           | <u>50,000</u>                        | <u>(62,982)</u>             | <u>(7,982)</u>  |

The notes set out on pages 17 to 23, form an integral part of and should be read in conjunction with these financial statements.



**ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**  
**(Incorporated in Malaysia)**

**STATEMENT OF CASH FLOWS**  
**FOR THE FINANCIAL YEAR ENDED 31 MARCH 2020**

|   | 2020<br>RM           | 2019<br>RM           |
|---|----------------------|----------------------|
| <b>CASH FLOWS FROM OPERATING ACTIVITIES</b>                                 |                      |                      |
| Loss for the Financial Year before<br>Taxation and Working Capital Changes  | (17,489)             | (33,335)             |
| Changes in Working Capital :  |                      |                      |
| Payables and Accruals   | 1,600                | 3,370                |
|   | <u>(15,889)</u>      | <u>(29,965)</u>      |
| <b>CASH FLOWS FROM FINANCING ACTIVITIES</b>                                 |                      |                      |
| Amount due to Holding Company   | <u>929</u>           | <u>51,834</u>        |
| <b>NET CHANGE IN CASH AND CASH EQUIVALENTS</b>                              | (14,960)             | 21,869               |
| <b>CASH AND CASH EQUIVALENTS AT THE<br/>BEGINNING OF THE FINANCIAL YEAR</b> | <u>64,131</u>        | <u>42,262</u>        |
| <b>CASH AND CASH EQUIVALENTS AT THE<br/>END OF THE FINANCIAL YEAR</b>       | <u><u>49,171</u></u> | <u><u>64,131</u></u> |

The notes set out on pages 17 to 23, form an integral part of and should be read in conjunction with these financial statements.

**ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**  
**(Incorporated in Malaysia)**

**NOTES TO THE FINANCIAL STATEMENTS: 31 MARCH 2020**

**1. PRINCIPAL ACTIVITIES**

The Company is a private limited company incorporated and domiciled in Malaysia.

The principal activities of the Company are intended to be the business of general trading.

The address of the registered office of the Company is as follows:

E-33A-05 Dataran 32,  
No. 2 Jalan 19/1,  
46300 Petaling Jaya  
Selangor Darul Ehsan.

The financial statements of the Company are reported in Ringgit Malaysia (RM).

**2. BASIS OF PREPARATION**

The financial statements of the Company have been properly prepared on a going concern basis under the historical cost convention and comply with the provisions of the Companies Act, 2016 and in accordance with Malaysian Private Entities Reporting Standard issued by the Malaysian Accounting Standards Board.

The Corona Virus (Covid-19) pandemic that started in January 2020 in Malaysia has resulted in significant uncertainties affecting the Company's ability to continue as a going concern. The Company has taken preventive measures and adopted prudent strategies to minimize the financial impacts of this crisis. The financial statements of the Company have been prepared on a going concern basis. This is because the Company has adequate cash and other resources, and has access to external funding from banks to enable the Company to continue to operate as a going concern.



### **3. SIGNIFICANT ACCOUNTING POLICIES**

#### **3.1 Cash and Cash Equivalents**

Cash and cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. They are held to meet short-term cash commitments instead of for investment or other purposes. If bank overdrafts are repayable on demand and form an integral part of cash management, bank overdrafts are a component of cash and cash equivalents.

#### **3.2 Liabilities and Provision**

Trade, other payables and accruals are stated at cost.

A provision is recognised only when (i) the entity has an obligation at the reporting date as a result of a past event; (ii) it is probable that the entity will be required to transfer economic benefits in settlement; and (iii) the amount of the obligation can be estimated reliably.

A provision is initially measured at the best estimate of the amount required to settle the obligation at the reporting date. When the effect of the time value of money is material, the amount of a provision shall be the present value of the amount expected to be required to settle the obligation.

Thereafter, the provision is reviewed at each reporting date and adjust it to reflect the current best estimate of the amount that would be required to settle the obligation at that reporting date. Any adjustments to the amounts previously recognised is recognised in statement of profit or loss. When a provision is measured at the present value of the amount expected to be required to settle the obligation, the unwinding of the discount is recognised as a finance cost in statement of profit or loss in the period it arises.

#### **3.3 Income Tax**

Current tax liability is recognised for tax payable on taxable profit for the current and past periods. If the amount paid for the current and past periods exceeds the amount payable for those periods, the excess is recognised as a current tax asset. Current tax liability or asset is measured at the amount it expects to pay or recover using the tax rates and laws that have been enacted or substantively enacted by the reporting date.

Deferred tax liability is recognised for all taxable temporary differences, except to the extent that the deferred tax liability arises from: (i) the initial recognition of goodwill; or (ii) the initial recognition of an asset or a liability in a transaction that is not a business combination, and at the time of the transaction, affects neither accounting profit nor taxable profit or tax loss.



### 3. SIGNIFICANT ACCOUNTING POLICIES (CONT'D)

#### 3.3 Income Tax (cont'd)

Deferred tax asset is recognised for all deductible temporary differences to the extent that it is probable that taxable profit will be available against which the deductible temporary difference can be utilized, unless the deferred tax asset arises from the initial recognition of an asset or a liability in a transaction that is not a business combination, and at the time of the transaction, affects neither accounting profit nor taxable profit or tax loss.

A deferred tax liability or asset is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date. The measurement of deferred tax liabilities and deferred tax assets reflects the tax consequences that would follow from the manner in which, at the reporting date, the carrying amount of the related assets and liabilities is expected to be recovered or settled.

Deferred tax asset is recognised for all deductible temporary differences arising from investments in subsidiaries, branches and associates and interests in joint ventures, only to the extent that it is probable that: (a) the temporary difference will reverse in the foreseeable future; and (b) taxable profit will be available against which the temporary difference can be utilized.

Deferred tax liability is recognised for all taxable temporary differences associated with investments in subsidiaries, branches and associates, and interests in joint ventures, except to the extent that (a) the parent, investor or venture is able to control the timing of the reversal of the temporary difference; and (b) it is probable that the temporary difference will not reverse in the foreseeable future.

Current or deferred tax assets and liabilities are not discounted.

#### 3.4 Financial Instruments

A financial instrument is a contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

##### (a) Initial recognition and measurement

On initial recognition, a financial asset or a financial liability is measured at the transaction price, including transaction costs. For a financial asset or a financial liability that is subsequently measured at fair value through profit or loss, transaction costs are expensed to statement of profit or loss when incurred.

A financial asset or a financial liability (including derivative instruments) is recognised only when an entity becomes a party to the contractual provisions of the instrument.

An arrangement constitutes a financial transaction, if payment is deferred beyond normal business terms. Under a financing transaction, a financial asset or a financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument as determined at initial recognition.



### 3. SIGNIFICANT ACCOUNTING POLICIES (CONT'D)

#### 3.4 Financial instruments (Cont'd)

##### (b) Subsequent measurement

Derivative financial instruments (other than derivatives designated as a hedging instrument) are measured at fair value and changes in fair value recognised in statement of profit or loss.

Debt instruments are measured at amortised cost using the effective interest method. Debt instruments that are classified as current assets or current liabilities are measured at the undiscounted amount of the cash or other considerations expected to be paid or received, unless the arrangement constitutes, in effect, a financing transaction.

Investments in non-convertible preference shares and non-puttable ordinary or preference shares, that are publicly traded or their value can otherwise be measured reliably without undue cost or effort, are measured at fair value with changes in fair value recognised in statement of profit or loss. All other such investments are measured at cost less impairment.

All financial assets are subject to review for impairment, except for financial assets measured at fair value through profit or loss.

##### (c) Impairment

At the end of each reporting period, financial assets that are measured at cost or amortised cost are assessed as to whether there is objective evidence of impairment. If there is objective evidence of impairment, an impairment loss is recognised in statement of profit or loss immediately.

For a financial asset measured at amortised cost, the impairment loss is the difference between the asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If such a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For a financial asset measured at cost less impairment, the impairment loss is the difference between the asset's carrying amount and the best estimate of the amount that would be received for the asset if it were to be sold at the reporting date.

If, in a subsequent period, the amount of an impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, the previously recognised impairment loss is reversed in statement of profit or loss



### 3. SIGNIFICANT ACCOUNTING POLICIES (CONT'D)

#### 3.4 Financial Instruments (cont'd)

##### (d) Derecognition

A financial asset is derecognized only when (i) the contractual rights to receive the cash flows from the financial asset expire or are settled; or (ii) the entity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, including circumstances when the entity acts only as a collecting agent of the transferee, and retains a significant risks and rewards of ownership of the financial asset or no continuing involvement in the control of the financial asset transferred.

A financial liability is derecognized only when it is extinguished, i.e. when the obligation specified in the contract is discharged, is cancelled or expired. A substantial modification of the terms of an existing financial liability is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability.

### 4. JUDGEMENTS AND ESTIMATION UNCERTAINTY

The key assumptions concerning the future, and other key sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year:

#### *Measurement of provision*

Management evaluates the estimates based on the historical experience and other inputs or assumptions, current developments and future events that are reasonably possible under the particular circumstances. A profitability-weighted estimate of the outflows required to settle the obligation is used. The actual outcome may differ from the estimates made and this may have a significant effect on the Company's financial position and financial performance.

### 5. CASH AND CASH EQUIVALENTS

|              | 2020<br>RM    | 2019<br>RM    |
|--------------|---------------|---------------|
| Cash at Bank | <u>49,171</u> | <u>64,131</u> |

### 6. SHARE APPLICATION MONIES

These relate to advance previously made to the Company and which are to be capitalized as shares subsequent to the financial year end.



**7. PAYABLES AND ACCRUALS**

|                | <b>2020<br/>RM</b> | <b>2019<br/>RM</b> |
|----------------|--------------------|--------------------|
| Other Payables | 4,682              | 3,082              |
| Accruals       | 2,300              | 2,300              |
|                | <u>6,982</u>       | <u>5,382</u>       |

**8. AMOUNT DUE TO HOLDING COMPANY**

The Holding Company is **Strides Pharma Global Pte. Ltd.**, a company incorporated in Singapore.

This amount is repayable on demand.

**9. OTHER INCOME**

|               | <b>2020<br/>RM</b> | <b>2019<br/>RM</b> |
|---------------|--------------------|--------------------|
| Bank Interest | <u>16</u>          | <u>19</u>          |

**10. TAXATION**

A reconciliation of the income tax expense on the loss for the financial period before taxation with the applicable statutory income tax rate is as follows:

|   | <b>2020<br/>RM</b> | <b>2019<br/>RM</b> |
|---|--------------------|--------------------|
| <b>Loss for the Financial<br/>Period before Taxation</b>    | <u>(17,488)</u>    | <u>(33,335)</u>    |
| Tax calculated at Malaysian tax rate<br>of 17% (2018 : 18%) | (2,973)            | (6,000)            |
| Expenses not deductible for tax purposes                    | <u>2,973</u>       | <u>6,000</u>       |
| <b>Total Tax Expense</b>                                    | <u>-</u>           | <u>-</u>           |

**11. SUBSEQUENT EVENT DURING THE REPORTING PERIOD**

The global Covid-19 Pandemic unfolded in Malaysia in January 2020 after the end of the reporting period. The government implemented lockdowns and other movement control orders to minimise the spread of the corona virus. This has resulted in severe restrictions of the Company's operations and activities that might lead to lossess of revenue and impairment of assets. However, the Company considers this pandemic to be a non-adjusting event after the end of the reporting period. The depth of the crisis and how long it will last is still unclear at the reporting date. As there are significant uncertainties, it is not possible to disclose the financial effects of this crisis on the Company's assets, liabilities and performance.

**12. FINANCIAL INSTRUMENTS**

|   | 2020<br>RM    | 2019<br>RM    |
|---|---------------|---------------|
| Financial Assets at amortised cost      | 49,171        | 64,131        |
| Financial Liabilities at amortised cost | <u>74,642</u> | <u>72,113</u> |

**13. AUTHORISATION FOR ISSUE OF FINANCIAL STATEMENTS**

The financial statements of the Company were authorized for issue by the Board of Directors on **18 SEP 2020**

*[The rest of this page has been intentionally left blank]*



**FOR MANAGEMENT  
PURPOSES ONLY**

**ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.  
(Incorporated in Malaysia)**

**DETAILED STATEMENT OF PROFIT OR LOSS  
FOR THE FINANCIAL YEAR ENDED  
31 MARCH 2020**

---

**ARROW LIFE SCIENCES (MALAYSIA) SDN. BHD.**  
**(Incorporated in Malaysia)**

|  |
|--|
| <p><b>FOR MANAGEMENT<br/>PURPOSES ONLY</b></p> |
|--|

**DETAILED STATEMENT OF PROFIT OR LOSS  
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2020**

|                                       | 2020<br>RM | 2019<br>RM |
|---------------------------------------|------------|------------|
| <b>GROSS INCOME</b>                   | -          | -          |
| <b>OTHER INCOME</b>                   | 16         | 19         |
| <b>TOTAL INCOME</b>                   | 16         | 19         |
| <b>LESS : ADMINISTRATIVE EXPENSES</b> |            |            |
| Attestation                           | 42         | -          |
| Audit Fees                            | 1,500      | 1,724      |
| Bank Charges                          | 8          | 14         |
| Business Development Expenses         | -          | 6,250      |
| Incorporation Expenses                | -          | -          |
| Printing and Stationery               | 483        | 832        |
| Product Registration Expenses         | 7,296      | 11,850     |
| Professional Fees                     | 1,420      | 2,597      |
| Regulatory Expenses                   | 450        | -          |
| Research and Development Expenses     | -          | 5,250      |
| Secretarial Filing Fees               | 4,800      | 4,127      |
| Service Tax                           | 471        | -          |
| Travelling                            | 107        | -          |
| Unrealised Foreign Exchange Loss      | 928        | 710        |
|                                       | 17,505     | 33,354     |
| <b>LOSS FOR THE FINANCIAL YEAR</b>    | (17,489)   | (33,335)   |